These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

622 related items for PubMed ID: 17311303

  • 1. Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial.
    Rynn M, Russell J, Erickson J, Detke MJ, Ball S, Dinkel J, Rickels K, Raskin J.
    Depress Anxiety; 2008; 25(3):182-9. PubMed ID: 17311303
    [Abstract] [Full Text] [Related]

  • 2. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I.
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [Abstract] [Full Text] [Related]

  • 3. Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials.
    Allgulander C, Hartford J, Russell J, Ball S, Erickson J, Raskin J, Rynn M.
    Curr Med Res Opin; 2007 Jun; 23(6):1245-52. PubMed ID: 17559726
    [Abstract] [Full Text] [Related]

  • 4. Examining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatment.
    Pollack MH, Endicott J, Liebowitz M, Russell J, Detke M, Spann M, Ball S, Swindle R.
    J Psychiatr Res; 2008 Oct; 42(12):1042-9. PubMed ID: 18221755
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
    Russell JM, Weisberg R, Fava M, Hartford JT, Erickson JS, D'Souza DN.
    Depress Anxiety; 2008 Oct; 25(7):E1-11. PubMed ID: 17587217
    [Abstract] [Full Text] [Related]

  • 6. Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial.
    Nicolini H, Bakish D, Duenas H, Spann M, Erickson J, Hallberg C, Ball S, Sagman D, Russell JM.
    Psychol Med; 2009 Feb; 39(2):267-76. PubMed ID: 18485261
    [Abstract] [Full Text] [Related]

  • 7. Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China.
    Wu WY, Wang G, Ball SG, Desaiah D, Ang QQ.
    Chin Med J (Engl); 2011 Oct; 124(20):3260-8. PubMed ID: 22088518
    [Abstract] [Full Text] [Related]

  • 8. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
    Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ.
    Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
    [Abstract] [Full Text] [Related]

  • 9. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder.
    Perahia DG, Pritchett YL, Kajdasz DK, Bauer M, Jain R, Russell JM, Walker DJ, Spencer KA, Froud DM, Raskin J, Thase ME.
    J Psychiatr Res; 2008 Jan; 42(1):22-34. PubMed ID: 17445831
    [Abstract] [Full Text] [Related]

  • 10. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA, Padmanabhan SK, Groark J, Brisard C, Farrington D.
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [Abstract] [Full Text] [Related]

  • 11. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM, Mallinckrodt CH, Prakash A, Watkin JG, Carter WP.
    Depress Anxiety; 2007 Jun; 24(1):41-52. PubMed ID: 16845641
    [Abstract] [Full Text] [Related]

  • 12. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 13. Duloxetine treatment for relapse prevention in adults with generalized anxiety disorder: a double-blind placebo-controlled trial.
    Davidson JR, Wittchen HU, Llorca PM, Erickson J, Detke M, Ball SG, Russell JM.
    Eur Neuropsychopharmacol; 2008 Sep; 18(9):673-81. PubMed ID: 18559291
    [Abstract] [Full Text] [Related]

  • 14. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Sep; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 15. Duloxetine in the treatment of Major Depressive Disorder: a comparison of efficacy in patients with and without melancholic features.
    Mallinckrodt CH, Watkin JG, Liu C, Wohlreich MM, Raskin J.
    BMC Psychiatry; 2005 Jan 04; 5():1. PubMed ID: 15631624
    [Abstract] [Full Text] [Related]

  • 16. A randomized controlled trial of duloxetine versus placebo in the treatment of nonmajor chronic depression.
    Hellerstein DJ, Stewart JW, McGrath PJ, Deliyannides DA, Batchelder ST, Black SR, Withers A, O'Shea D, Chen Y.
    J Clin Psychiatry; 2012 Jul 04; 73(7):984-91. PubMed ID: 22901348
    [Abstract] [Full Text] [Related]

  • 17. Deramciclane in the treatment of generalized anxiety disorder: a placebo-controlled, double-blind, dose-finding study.
    Naukkarinen H, Raassina R, Penttinen J, Ahokas A, Jokinen R, Koponen H, Lepola U, Kanerva H, Lehtonen L, Pohjalainen T, Partanen A, Mäki-Ikola O, Rouru J, Deramciclane Dose-Finding Study Group.
    Eur Neuropsychopharmacol; 2005 Dec 04; 15(6):617-23. PubMed ID: 15949921
    [Abstract] [Full Text] [Related]

  • 18. Gepirone extended-release treatment of anxious depression: evidence from a retrospective subgroup analysis in patients with major depressive disorder.
    Alpert JE, Franznick DA, Hollander SB, Fava M.
    J Clin Psychiatry; 2004 Aug 04; 65(8):1069-75. PubMed ID: 15323591
    [Abstract] [Full Text] [Related]

  • 19. Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trial.
    Katzman MA, Vermani M, Jacobs L, Marcus M, Kong B, Lessard S, Galarraga W, Struzik L, Gendron A.
    J Anxiety Disord; 2008 Dec 04; 22(8):1480-6. PubMed ID: 18455360
    [Abstract] [Full Text] [Related]

  • 20. Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale.
    Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A.
    Int Clin Psychopharmacol; 2011 Mar 04; 26(2):75-83. PubMed ID: 21102344
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.